B+
Bull case
25%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
IMNM
ImmunomeANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-24
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+87.6
Score
AI commentary
The company source is concrete: Immunome’s August 11 SEC 8-K Exhibit 99.1 reported Q2 results, RINGSIDE outcomes, FDA acceptance of the varegacestat NDA, pipeline progress, and runway into 2028. Price action was initially positive but volatile, with gains on August 11-12 followed by a decline on August 13; the latest RankAlpha anchor was $28.52 on August 21. Secondary analyst data show Wedbush and Truist raised targets on August 12 while maintaining positive ratings, but no verified consensus EPS surprise or broader estimate-revision series is available. The deterministic prior remains negative, so this is a milestone-driven monitoring setup rather than a high-conviction long. [#SEC-8K-2026-08-11] https://stockanalysis.com/stocks/imnm/history/
RankAlpha Sentiment Codex - 2026-08-24
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-24catalystPost-earnings pipeline execution remains the near-term read-throughMedium impact
The SEC Exhibit 99.1 filed with the August 11 8-K confirmed strong RINGSIDE efficacy, FDA acceptance of the varegacestat NDA, first-patient dosing for IM-1617 and IM-3050, and cash expected to fund operations into 2028. Available price data show a positive initial move after the release but subsequent volatility: shares rose 2.18% on August 11 and 6.63% on August 12, then fell 5.61% on August 13. The packet does not provide a reliable consensus comparison, so this is a milestone read-through rather than a quantified earnings-surprise thesis. [#SEC-8K-2026-08-11] https://stockanalysis.com/stocks/imnm/history/
2026-12-31catalystInitial IM-1021 lymphoma data expected in 2026High impact
The Phase 1 IM-1021 study is ongoing, with objective responses observed at multiple dose levels, and initial lymphoma data are expected in 2026. Early clinical data could validate a second asset, but the dataset and durability remain unproven. [#SEC-8K-2026-08-11]
2026-12-31catalystAdditional clinical and IND milestones across the oncology pipelineHigh impact
IM-1617 and IM-3050 have entered Phase 1, while Immunome expects IND submissions for IM-1340 and IM-1335 in mid- and late-2026. These milestones increase pipeline breadth but remain early-stage and safety- and enrollment-dependent. [#SEC-8K-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-24 • Updated nightlySource: Internal modelMethodology